Summary of Clinical Use

Briquilimab has progressed to clinical trial as a novel therapeutic for mast cell-driven (atopic) chronic urticaria [2], and for efficacy as a component of pre-hematopoietic stem cell transplantation conditioning regimen.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT06162728	Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)	Phase 1/Phase 2 Interventional	Jasper Therapeutics, Inc.
NCT06353971	A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines	Phase 1/Phase 2 Interventional	Jasper Therapeutics, Inc.
NCT04784052	Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab	Phase 1/Phase 2 Interventional	Stanford University
NCT05357482	Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia	Phase 1/Phase 2 Interventional	National Institutes of Health Clinical Center (CC)
NCT05903274	JSP191 (Briquilimab) in Subjects With LR-MDS	Phase 1 Interventional	Jasper Therapeutics, Inc.
NCT02963064	JSP191 Antibody Targeting Conditioning in SCID Patients	Phase 1/Phase 2 Interventional	Jasper Therapeutics, Inc.		1
NCT04429191	JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation	Phase 1 Interventional	Jasper Therapeutics, Inc.		1